Wockhardt jumps up over 3%

Wockhardt showed a sudden spurt of over 3% to Rs.505.15 and it continues to remain in the green.

Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for Imatinib Mesylate, which is used to treat many kinds of cancers and tumors. Wockhardt's Imatinib Mesylate tablets are a generic version of Gleevec, marketed in USA and other countries by Novartis.

Wockhardt will be launching this product in the United States, in a short period of time.

The product is being manufactured at a contract manufacturing facility, based near Hyderabad, India.